Loading…
The sensitivity of gastric cancer to trastuzumab is regulated by the miR‐223/FBXW7 pathway
A recent large‐scale phase III study (the ToGA trial) demonstrated the significant efficacy of trastuzumab combined with chemotherapy in patients with HER2‐positive gastric cancer. Although trastuzumab has become a key drug in cancer treatment, the resistance of breast cancer to trastuzumab is a maj...
Saved in:
| Published in: | International journal of cancer 2015-04, Vol.136 (7), p.1537-1545 |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | 1545 |
| container_issue | 7 |
| container_start_page | 1537 |
| container_title | International journal of cancer |
| container_volume | 136 |
| creator | Eto, Kojiro Iwatsuki, Masaaki Watanabe, Masayuki Ishimoto, Takatsugu Ida, Satoshi Imamura, Yu Iwagami, Shiro Baba, Yoshifumi Sakamoto, Yasuo Miyamoto, Yuji Yoshida, Naoya Baba, Hideo |
| description | A recent large‐scale phase III study (the ToGA trial) demonstrated the significant efficacy of trastuzumab combined with chemotherapy in patients with HER2‐positive gastric cancer. Although trastuzumab has become a key drug in cancer treatment, the resistance of breast cancer to trastuzumab is a major problem in clinical practice. However, it is unclear whether similar mechanisms of trastuzumab resistance are involved in gastric cancer (GC). The aim of the current study was to identify a novel micro‐RNA (miR)/gene pathway that regulates the sensitivity of HER2‐positive GC cells to trastuzumab. We focused on F‐box and WD repeat domain‐containing 7 (FBXW7), which is one of the major causes of drug resistance. We also identified miR‐223, which can regulate FBXW7, using miR quantitative reverse transcription‐PCR array analysis using by resistance cell line, which we established. Overexpression of miR‐223 decreased FBXW7 expression and the sensitivity of GC cells to trastuzumab, while suppression of miR‐223 restored FBXW7 expression and the sensitivity of GC cells to trastuzumab. Moreover, overexpression of miR‐223 significantly suppressed trastuzumab‐induced apoptosis. This study is the first report to reveal that the miR‐223/FBXW7 pathway regulates the sensitivity of a HER2‐positive GC cell line to trastuzumab through the modulation of apoptosis. These findings suggest that this pathway can be crucial for the mechanism of trastuzumab resistance in GC, which may lead to the development of individualized treatment in clinical practice.
What's new?
The monoclonal antibody trastuzumab is effective against HER2‐positive gastric cancers (GCs). However, as with breast cancer, many GCs develop resistance to this drug. In this study, the authors found that a microRNA called “miR‐233” interacts with a gene called “FBXW7” to regulate the sensitivity of HER2‐positive GC cells to trastuzumab, by altering apoptosis. These results suggest that the miR‐223/FBXW7 pathway may be a valuable therapeutic target to decrease resistance of GC to trastuzumab. |
| doi_str_mv | 10.1002/ijc.29168 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1652446980</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3556612371</sourcerecordid><originalsourceid>FETCH-LOGICAL-j4508-d1a029c8917abac378aa5817bdc11531fdceaf062b34b1aa21445b5af072e82a3</originalsourceid><addsrcrecordid>eNpdkc1Kw0AUhQdRtFYXvoAMuHGTdu4kk0mWWqw_FARRdCGEm8lUpyRNzUwsceUj-Iw-iWOrLlzdyz0fh8M9hBwAGwBjfGhmasBTiJMN0gOWyoBxEJuk5zUWSAjjHbJr7YwxAMGibbLDBYhU8rRHHm-fNbV6bo0zr8Z1tJ7SJ7SuMYoqnCvdUFdT1_hT-9ZWmFNjaaOf2hKdLmjeUecNKnPz-f7BeTgcnz7cS7pA97zEbo9sTbG0ev9n9snd-Ox2dBFMrs8vRyeTYBYJlgQFIOOpSlKQmKMKZYIoEpB5oXzgEKaF0jhlMc_DKAdEDlEkcuFPkuuEY9gnx2vfRVO_tNq6rDJW6bLEua5bm0EseBTFacI8evQPndVtM_fpPOXTRKHkiacOf6g2r3SRLRpTYdNlv3_zwHANLE2puz8dWPZdSOYLyVaFZJdXo9USfgFX9nyK</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1645043728</pqid></control><display><type>article</type><title>The sensitivity of gastric cancer to trastuzumab is regulated by the miR‐223/FBXW7 pathway</title><source>Wiley</source><creator>Eto, Kojiro ; Iwatsuki, Masaaki ; Watanabe, Masayuki ; Ishimoto, Takatsugu ; Ida, Satoshi ; Imamura, Yu ; Iwagami, Shiro ; Baba, Yoshifumi ; Sakamoto, Yasuo ; Miyamoto, Yuji ; Yoshida, Naoya ; Baba, Hideo</creator><creatorcontrib>Eto, Kojiro ; Iwatsuki, Masaaki ; Watanabe, Masayuki ; Ishimoto, Takatsugu ; Ida, Satoshi ; Imamura, Yu ; Iwagami, Shiro ; Baba, Yoshifumi ; Sakamoto, Yasuo ; Miyamoto, Yuji ; Yoshida, Naoya ; Baba, Hideo</creatorcontrib><description>A recent large‐scale phase III study (the ToGA trial) demonstrated the significant efficacy of trastuzumab combined with chemotherapy in patients with HER2‐positive gastric cancer. Although trastuzumab has become a key drug in cancer treatment, the resistance of breast cancer to trastuzumab is a major problem in clinical practice. However, it is unclear whether similar mechanisms of trastuzumab resistance are involved in gastric cancer (GC). The aim of the current study was to identify a novel micro‐RNA (miR)/gene pathway that regulates the sensitivity of HER2‐positive GC cells to trastuzumab. We focused on F‐box and WD repeat domain‐containing 7 (FBXW7), which is one of the major causes of drug resistance. We also identified miR‐223, which can regulate FBXW7, using miR quantitative reverse transcription‐PCR array analysis using by resistance cell line, which we established. Overexpression of miR‐223 decreased FBXW7 expression and the sensitivity of GC cells to trastuzumab, while suppression of miR‐223 restored FBXW7 expression and the sensitivity of GC cells to trastuzumab. Moreover, overexpression of miR‐223 significantly suppressed trastuzumab‐induced apoptosis. This study is the first report to reveal that the miR‐223/FBXW7 pathway regulates the sensitivity of a HER2‐positive GC cell line to trastuzumab through the modulation of apoptosis. These findings suggest that this pathway can be crucial for the mechanism of trastuzumab resistance in GC, which may lead to the development of individualized treatment in clinical practice.
What's new?
The monoclonal antibody trastuzumab is effective against HER2‐positive gastric cancers (GCs). However, as with breast cancer, many GCs develop resistance to this drug. In this study, the authors found that a microRNA called “miR‐233” interacts with a gene called “FBXW7” to regulate the sensitivity of HER2‐positive GC cells to trastuzumab, by altering apoptosis. These results suggest that the miR‐223/FBXW7 pathway may be a valuable therapeutic target to decrease resistance of GC to trastuzumab.</description><identifier>ISSN: 0020-7136</identifier><identifier>EISSN: 1097-0215</identifier><identifier>DOI: 10.1002/ijc.29168</identifier><identifier>PMID: 25159729</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Antibodies, Monoclonal, Humanized - therapeutic use ; Antineoplastic Agents - therapeutic use ; Apoptosis ; Apoptosis - drug effects ; Apoptosis - genetics ; Cancer ; Cell Cycle Proteins - genetics ; Cell Line, Tumor ; Chemotherapy ; Clinical medicine ; Drug resistance ; Drug Resistance, Neoplasm - genetics ; F-Box Proteins - genetics ; F-Box-WD Repeat-Containing Protein 7 ; Gastric cancer ; Gene Expression ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Gene Knockdown Techniques ; Humans ; Medical research ; MicroRNAs - genetics ; Monoclonal antibodies ; RNA Interference ; Stomach Neoplasms - drug therapy ; Stomach Neoplasms - genetics ; Trastuzumab ; Ubiquitin-Protein Ligases - genetics</subject><ispartof>International journal of cancer, 2015-04, Vol.136 (7), p.1537-1545</ispartof><rights>2014 UICC</rights><rights>2014 UICC.</rights><rights>2015 UICC</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fijc.29168$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fijc.29168$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,786,790,27957,27958,50923,51032</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25159729$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Eto, Kojiro</creatorcontrib><creatorcontrib>Iwatsuki, Masaaki</creatorcontrib><creatorcontrib>Watanabe, Masayuki</creatorcontrib><creatorcontrib>Ishimoto, Takatsugu</creatorcontrib><creatorcontrib>Ida, Satoshi</creatorcontrib><creatorcontrib>Imamura, Yu</creatorcontrib><creatorcontrib>Iwagami, Shiro</creatorcontrib><creatorcontrib>Baba, Yoshifumi</creatorcontrib><creatorcontrib>Sakamoto, Yasuo</creatorcontrib><creatorcontrib>Miyamoto, Yuji</creatorcontrib><creatorcontrib>Yoshida, Naoya</creatorcontrib><creatorcontrib>Baba, Hideo</creatorcontrib><title>The sensitivity of gastric cancer to trastuzumab is regulated by the miR‐223/FBXW7 pathway</title><title>International journal of cancer</title><addtitle>Int J Cancer</addtitle><description>A recent large‐scale phase III study (the ToGA trial) demonstrated the significant efficacy of trastuzumab combined with chemotherapy in patients with HER2‐positive gastric cancer. Although trastuzumab has become a key drug in cancer treatment, the resistance of breast cancer to trastuzumab is a major problem in clinical practice. However, it is unclear whether similar mechanisms of trastuzumab resistance are involved in gastric cancer (GC). The aim of the current study was to identify a novel micro‐RNA (miR)/gene pathway that regulates the sensitivity of HER2‐positive GC cells to trastuzumab. We focused on F‐box and WD repeat domain‐containing 7 (FBXW7), which is one of the major causes of drug resistance. We also identified miR‐223, which can regulate FBXW7, using miR quantitative reverse transcription‐PCR array analysis using by resistance cell line, which we established. Overexpression of miR‐223 decreased FBXW7 expression and the sensitivity of GC cells to trastuzumab, while suppression of miR‐223 restored FBXW7 expression and the sensitivity of GC cells to trastuzumab. Moreover, overexpression of miR‐223 significantly suppressed trastuzumab‐induced apoptosis. This study is the first report to reveal that the miR‐223/FBXW7 pathway regulates the sensitivity of a HER2‐positive GC cell line to trastuzumab through the modulation of apoptosis. These findings suggest that this pathway can be crucial for the mechanism of trastuzumab resistance in GC, which may lead to the development of individualized treatment in clinical practice.
What's new?
The monoclonal antibody trastuzumab is effective against HER2‐positive gastric cancers (GCs). However, as with breast cancer, many GCs develop resistance to this drug. In this study, the authors found that a microRNA called “miR‐233” interacts with a gene called “FBXW7” to regulate the sensitivity of HER2‐positive GC cells to trastuzumab, by altering apoptosis. These results suggest that the miR‐223/FBXW7 pathway may be a valuable therapeutic target to decrease resistance of GC to trastuzumab.</description><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Apoptosis - genetics</subject><subject>Cancer</subject><subject>Cell Cycle Proteins - genetics</subject><subject>Cell Line, Tumor</subject><subject>Chemotherapy</subject><subject>Clinical medicine</subject><subject>Drug resistance</subject><subject>Drug Resistance, Neoplasm - genetics</subject><subject>F-Box Proteins - genetics</subject><subject>F-Box-WD Repeat-Containing Protein 7</subject><subject>Gastric cancer</subject><subject>Gene Expression</subject><subject>Gene Expression Profiling</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Gene Knockdown Techniques</subject><subject>Humans</subject><subject>Medical research</subject><subject>MicroRNAs - genetics</subject><subject>Monoclonal antibodies</subject><subject>RNA Interference</subject><subject>Stomach Neoplasms - drug therapy</subject><subject>Stomach Neoplasms - genetics</subject><subject>Trastuzumab</subject><subject>Ubiquitin-Protein Ligases - genetics</subject><issn>0020-7136</issn><issn>1097-0215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNpdkc1Kw0AUhQdRtFYXvoAMuHGTdu4kk0mWWqw_FARRdCGEm8lUpyRNzUwsceUj-Iw-iWOrLlzdyz0fh8M9hBwAGwBjfGhmasBTiJMN0gOWyoBxEJuk5zUWSAjjHbJr7YwxAMGibbLDBYhU8rRHHm-fNbV6bo0zr8Z1tJ7SJ7SuMYoqnCvdUFdT1_hT-9ZWmFNjaaOf2hKdLmjeUecNKnPz-f7BeTgcnz7cS7pA97zEbo9sTbG0ev9n9snd-Ox2dBFMrs8vRyeTYBYJlgQFIOOpSlKQmKMKZYIoEpB5oXzgEKaF0jhlMc_DKAdEDlEkcuFPkuuEY9gnx2vfRVO_tNq6rDJW6bLEua5bm0EseBTFacI8evQPndVtM_fpPOXTRKHkiacOf6g2r3SRLRpTYdNlv3_zwHANLE2puz8dWPZdSOYLyVaFZJdXo9USfgFX9nyK</recordid><startdate>20150401</startdate><enddate>20150401</enddate><creator>Eto, Kojiro</creator><creator>Iwatsuki, Masaaki</creator><creator>Watanabe, Masayuki</creator><creator>Ishimoto, Takatsugu</creator><creator>Ida, Satoshi</creator><creator>Imamura, Yu</creator><creator>Iwagami, Shiro</creator><creator>Baba, Yoshifumi</creator><creator>Sakamoto, Yasuo</creator><creator>Miyamoto, Yuji</creator><creator>Yoshida, Naoya</creator><creator>Baba, Hideo</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7T5</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20150401</creationdate><title>The sensitivity of gastric cancer to trastuzumab is regulated by the miR‐223/FBXW7 pathway</title><author>Eto, Kojiro ; Iwatsuki, Masaaki ; Watanabe, Masayuki ; Ishimoto, Takatsugu ; Ida, Satoshi ; Imamura, Yu ; Iwagami, Shiro ; Baba, Yoshifumi ; Sakamoto, Yasuo ; Miyamoto, Yuji ; Yoshida, Naoya ; Baba, Hideo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j4508-d1a029c8917abac378aa5817bdc11531fdceaf062b34b1aa21445b5af072e82a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Apoptosis - genetics</topic><topic>Cancer</topic><topic>Cell Cycle Proteins - genetics</topic><topic>Cell Line, Tumor</topic><topic>Chemotherapy</topic><topic>Clinical medicine</topic><topic>Drug resistance</topic><topic>Drug Resistance, Neoplasm - genetics</topic><topic>F-Box Proteins - genetics</topic><topic>F-Box-WD Repeat-Containing Protein 7</topic><topic>Gastric cancer</topic><topic>Gene Expression</topic><topic>Gene Expression Profiling</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Gene Knockdown Techniques</topic><topic>Humans</topic><topic>Medical research</topic><topic>MicroRNAs - genetics</topic><topic>Monoclonal antibodies</topic><topic>RNA Interference</topic><topic>Stomach Neoplasms - drug therapy</topic><topic>Stomach Neoplasms - genetics</topic><topic>Trastuzumab</topic><topic>Ubiquitin-Protein Ligases - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Eto, Kojiro</creatorcontrib><creatorcontrib>Iwatsuki, Masaaki</creatorcontrib><creatorcontrib>Watanabe, Masayuki</creatorcontrib><creatorcontrib>Ishimoto, Takatsugu</creatorcontrib><creatorcontrib>Ida, Satoshi</creatorcontrib><creatorcontrib>Imamura, Yu</creatorcontrib><creatorcontrib>Iwagami, Shiro</creatorcontrib><creatorcontrib>Baba, Yoshifumi</creatorcontrib><creatorcontrib>Sakamoto, Yasuo</creatorcontrib><creatorcontrib>Miyamoto, Yuji</creatorcontrib><creatorcontrib>Yoshida, Naoya</creatorcontrib><creatorcontrib>Baba, Hideo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eto, Kojiro</au><au>Iwatsuki, Masaaki</au><au>Watanabe, Masayuki</au><au>Ishimoto, Takatsugu</au><au>Ida, Satoshi</au><au>Imamura, Yu</au><au>Iwagami, Shiro</au><au>Baba, Yoshifumi</au><au>Sakamoto, Yasuo</au><au>Miyamoto, Yuji</au><au>Yoshida, Naoya</au><au>Baba, Hideo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The sensitivity of gastric cancer to trastuzumab is regulated by the miR‐223/FBXW7 pathway</atitle><jtitle>International journal of cancer</jtitle><addtitle>Int J Cancer</addtitle><date>2015-04-01</date><risdate>2015</risdate><volume>136</volume><issue>7</issue><spage>1537</spage><epage>1545</epage><pages>1537-1545</pages><issn>0020-7136</issn><eissn>1097-0215</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>A recent large‐scale phase III study (the ToGA trial) demonstrated the significant efficacy of trastuzumab combined with chemotherapy in patients with HER2‐positive gastric cancer. Although trastuzumab has become a key drug in cancer treatment, the resistance of breast cancer to trastuzumab is a major problem in clinical practice. However, it is unclear whether similar mechanisms of trastuzumab resistance are involved in gastric cancer (GC). The aim of the current study was to identify a novel micro‐RNA (miR)/gene pathway that regulates the sensitivity of HER2‐positive GC cells to trastuzumab. We focused on F‐box and WD repeat domain‐containing 7 (FBXW7), which is one of the major causes of drug resistance. We also identified miR‐223, which can regulate FBXW7, using miR quantitative reverse transcription‐PCR array analysis using by resistance cell line, which we established. Overexpression of miR‐223 decreased FBXW7 expression and the sensitivity of GC cells to trastuzumab, while suppression of miR‐223 restored FBXW7 expression and the sensitivity of GC cells to trastuzumab. Moreover, overexpression of miR‐223 significantly suppressed trastuzumab‐induced apoptosis. This study is the first report to reveal that the miR‐223/FBXW7 pathway regulates the sensitivity of a HER2‐positive GC cell line to trastuzumab through the modulation of apoptosis. These findings suggest that this pathway can be crucial for the mechanism of trastuzumab resistance in GC, which may lead to the development of individualized treatment in clinical practice.
What's new?
The monoclonal antibody trastuzumab is effective against HER2‐positive gastric cancers (GCs). However, as with breast cancer, many GCs develop resistance to this drug. In this study, the authors found that a microRNA called “miR‐233” interacts with a gene called “FBXW7” to regulate the sensitivity of HER2‐positive GC cells to trastuzumab, by altering apoptosis. These results suggest that the miR‐223/FBXW7 pathway may be a valuable therapeutic target to decrease resistance of GC to trastuzumab.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>25159729</pmid><doi>10.1002/ijc.29168</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0020-7136 |
| ispartof | International journal of cancer, 2015-04, Vol.136 (7), p.1537-1545 |
| issn | 0020-7136 1097-0215 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1652446980 |
| source | Wiley |
| subjects | Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents - therapeutic use Apoptosis Apoptosis - drug effects Apoptosis - genetics Cancer Cell Cycle Proteins - genetics Cell Line, Tumor Chemotherapy Clinical medicine Drug resistance Drug Resistance, Neoplasm - genetics F-Box Proteins - genetics F-Box-WD Repeat-Containing Protein 7 Gastric cancer Gene Expression Gene Expression Profiling Gene Expression Regulation, Neoplastic Gene Knockdown Techniques Humans Medical research MicroRNAs - genetics Monoclonal antibodies RNA Interference Stomach Neoplasms - drug therapy Stomach Neoplasms - genetics Trastuzumab Ubiquitin-Protein Ligases - genetics |
| title | The sensitivity of gastric cancer to trastuzumab is regulated by the miR‐223/FBXW7 pathway |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T16%3A53%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20sensitivity%20of%20gastric%20cancer%20to%20trastuzumab%20is%20regulated%20by%20the%20miR%E2%80%90223/FBXW7%20pathway&rft.jtitle=International%20journal%20of%20cancer&rft.au=Eto,%20Kojiro&rft.date=2015-04-01&rft.volume=136&rft.issue=7&rft.spage=1537&rft.epage=1545&rft.pages=1537-1545&rft.issn=0020-7136&rft.eissn=1097-0215&rft_id=info:doi/10.1002/ijc.29168&rft_dat=%3Cproquest_pubme%3E3556612371%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-j4508-d1a029c8917abac378aa5817bdc11531fdceaf062b34b1aa21445b5af072e82a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1645043728&rft_id=info:pmid/25159729&rfr_iscdi=true |